Curcumin-Based Niche Solutions for High-Impact Environments

Publication ID: 24-11857594_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Curcumin-Based Niche Solutions for High-Impact Environments,” Published Technical Disclosure No. 24-11857594_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857594_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,594.

Summary of the Inventive Concept

Adapting curcumin compositions as neurokinin 3 receptor antagonists for specialized, high-stakes applications, including disaster relief, high-security environments, and extreme weather conditions.

Background and Problem Solved

The original patent disclosed curcumin compositions as neurokinin 3 receptor antagonists, but it did not address the limitations of using these compositions in extreme or high-security environments. The new inventive concept addresses this gap by adapting the curcumin compositions for use in disaster relief, high-security environments, and extreme weather conditions, thereby expanding their applicability and potential impact.

Detailed Description of the Inventive Concept

The new inventive concept involves adapting curcumin compositions to address specific challenges in high-impact environments. For example, a system for disaster relief may comprise a curcumin composition and a delivery vehicle adapted for aerial deployment in extreme weather conditions. Alternatively, a method for providing neurokinin 3 receptor antagonist therapy in high-security environments may involve administering a curcumin composition to an individual in need thereof. The curcumin-based composition may be formulated with a synergistic ratio of curcumin to green tea extract to phycocyanin of about 5:2:1, suitable for use in emergency response kits.

Novelty and Inventive Step

The new inventive concept introduces novel and non-obvious adaptations of curcumin compositions for use in high-impact environments, which are not anticipated by the original patent. The inventive step lies in recognizing the potential of curcumin compositions in these specialized contexts and developing tailored solutions to address the unique challenges and constraints of these environments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include adapting curcumin compositions for use in remote medical treatment, telemedicine platforms, or portable kits for extreme environments. Variations may include different synergistic ratios of curcumin to green tea extract to phycocyanin, or alternative delivery vehicles and formulations.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the fields of disaster relief, high-security environments, and extreme weather conditions. Target industries may include emergency response services, government agencies, and private companies operating in high-risk environments.

CPC Classifications

SectionClassGroup
A A61 A61K36/9066
A A61 A61K31/26
A A61 A61K36/82
A A61 A61P15/12

Field of Art

Pharmaceutical compositions and neurokinin receptor antagonist therapies, with expertise in natural compound formulations, drug delivery systems, and medical treatment methodologies

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical researcher or clinical pharmacologist with advanced degrees in biochemistry or pharmacology, experienced in natural compound extraction, formulation optimization, and therapeutic application development

Obviousness Rationale

A person skilled in the art would recognize the inherent adaptability of curcumin-based compositions for specialized medical applications by leveraging the foundational teachings of the source patent. The disclosed variations represent predictable extensions of known neurokinin 3 receptor antagonist technologies, utilizing standard pharmaceutical engineering techniques to modify delivery mechanisms and application contexts. The PTD's proposed adaptations follow logical design progression from the original compositional framework, demonstrating incremental innovation rather than non-obvious invention.

Obvious Combinations & Variations

Source Patent Element
Curcumin composition with specific synergistic ratios of curcumin, green tea extract, and phycocyanin
PTD Variation
Adapting the composition ratio to 5:2:1 for emergency response kits
Obviousness Reasoning
Routine optimization of known compositional ratios within a predictable range, representing a design choice based on intended application context
Source Patent Element
Neurokinin 3 receptor antagonist therapeutic approach
PTD Variation
Specialized delivery systems for high-security and extreme environment applications
Obviousness Reasoning
Applying known pharmaceutical formulation techniques to extend therapeutic accessibility, representing a standard engineering problem-solving approach
Source Patent Element
Curcumin-based medical composition
PTD Variation
Telemedicine platform integration for remote medical treatment
Obviousness Reasoning
Predictable technological convergence combining known medical composition with emerging digital health delivery mechanisms
Source Patent Element
Compositional ratios of natural compounds
PTD Variation
Portable kit with temperature-resistant protective casing
Obviousness Reasoning
Routine product engineering to enhance stability and transportability of known pharmaceutical compositions
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857594 and the published technical disclosure, a person having ordinary skill in the art would find the proposed variations obvious and lacking inventive step. The disclosed adaptations represent predictable extensions of existing neurokinin 3 receptor antagonist technologies, utilizing standard pharmaceutical engineering techniques to modify compositional ratios, delivery mechanisms, and application contexts without demonstrating non-obvious innovation.

Original Patent Information

Patent NumberUS 11,857,594
TitleCurcumin compositions and methods of use as an NK3 antagonist
Assignee(s)JDS Therapeutics, LLC